Status:

RECRUITING

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Lead Sponsor:

CellCentric Ltd.

Conditions:

Haematological Malignancy

Acute Myeloid Leukemia

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk M...

Detailed Description

This includes patients with Peripheral T-cell lymphoma.

Eligibility Criteria

Inclusion

  • Provision of consent
  • ECOG performance status 0-2
  • Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML)
  • Must have previously received standard therapy
  • Adequate organ function

Exclusion

  • Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
  • Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment
  • Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
  • Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment
  • Patients should discontinue statins prior to starting study treatment
  • CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
  • Any unresolved reversible toxicities from prior therapy \>CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)
  • Any evidence of severe or uncontrolled systemic diseases
  • Any known uncontrolled inter-current illness
  • QTcF prolongation (\> 470 msec)

Key Trial Info

Start Date :

August 9 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 31 2027

Estimated Enrollment :

250 Patients enrolled

Trial Details

Trial ID

NCT04068597

Start Date

August 9 2019

End Date

March 31 2027

Last Update

December 18 2025

Active Locations (39)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (39 locations)

1

Emory Winship Cancer Institute

Atlanta, Georgia, United States, 30322

2

Community Health Network

Indianapolis, Indiana, United States, 46227

3

The Center for Cancer and Blood Disorders (CCBD)

Bethesda, Maryland, United States, 20817

4

Nebraska Cancer Specialists

Omaha, Nebraska, United States, 68130

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | DecenTrialz